Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00615784 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00615784 is a Phase 2 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 24 participants.
The verdict
NCT00615784, a Phase 2 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the activity of bexarotene, a retinoic acid class drug, in patients with Acute Myeloid Leukemia (AML) that has returned after or is resistant to standard chemotherapy or are otherwise not eligible for conventional chemotherapy. Retinoic acids are a class of drugs related to Vitamin A, and have a wide range of effects within normal and malignant cells that affect cell growth and cell death.
Interventions
- DRUG Bexarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-05-25 |
| Est. Completion | 2013-11-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00615784
The ClinicalTrials.gov registry entry for NCT00615784 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bexarotene is the first listed.
NCT00615784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00615784 about?
NCT00615784 is a clinical study titled "Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia". The purpose of this study is to evaluate the activity of bexarotene, a retinoic acid class drug, in patients with Acute Myeloid Leukemia (AML) that has returned after or is resistant to standard chemotherapy or are otherwise not eligible for conventional chemotherapy. Retinoic acids are a class of d...
What is the current status of trial NCT00615784?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2010-05-25. Estimated completion is 2013-11-08.
What interventions are being tested in trial NCT00615784?
The interventions under investigation include: Bexarotene (DRUG).
Who is sponsoring clinical trial NCT00615784?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.